Show simple item record

dc.contributor.authorKlampatsa, A
dc.contributor.authorAlbelda, SM
dc.date.accessioned2020-09-30T14:05:15Z
dc.date.issued2020-01
dc.identifier.citationJournal of cellular immunology, 2020, 2 (4), pp. 192 - 200
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4106
dc.identifier.eissn2689-2812
dc.identifier.doi10.33696/immunology.2.042
dc.description.abstractMalignant mesothelioma is a relatively rare malignancy arising in the body's serosal surfaces, with malignant pleural mesothelioma (MPM) being the most common type. It is characterized by local spread within the thorax, poor prognosis and resistance to treatment. The development of various immunotherapeutic options has provided a new way- and hope- in treating cancer patients. Chimeric antigen receptor (CAR) T cell therapy has been proven very successful in treating hematological cancers, like leukemias and lymphomas, and its use is now being tested in solid tumors. CARs that recognize and bind to a specific tumor-associated antigen on the tumor's cell surface, are engineered and transduced into T cells. Interaction of the CAR T cell with the tumor then results in T cell activation and subsequent tumor cell lysis. In this review, we provide a current update on our previous comprehensive study summarizing the CAR T cell preclinical studies and clinical trials in MM, and discuss the future perspectives of CAR T cell therapy in this disease.
dc.formatPrint
dc.format.extent192 - 200
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleCurrent Advances in CAR T Cell Therapy for Malignant Mesothelioma.
dc.typeJournal Article
dcterms.dateAccepted2020-06-22
rioxxterms.versionofrecord10.33696/immunology.2.042
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of cellular immunology
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Thoracic Oncology Immunotherapy Group (TOIG)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Thoracic Oncology Immunotherapy Group (TOIG)
pubs.publication-statusPublished
pubs.volume2
pubs.embargo.termsNot known
icr.researchteamThoracic Oncology Immunotherapy Group (TOIG)en_US
dc.contributor.icrauthorKlampatsa, Asteroen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0